Good morning :)
$
₹
Prothena Corporation plc

Prothena Corporation plc

PRTA

NASDAQ
Asset Logo

Prothena Corporation plc

PRTA

NASDAQ
$8.432.87% (+0.23)
$
₹
$8.432.87% (+0.23)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $421.0M the stock is ranked 3476

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.47
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.82
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.8
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-80.68%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 7 analysts reports

Buy
4 analysts
Hold
2 analysts
Sell
1 analyst

Price Upside

+160.98%

Earnings Growth

+116.08%

Rev. Growth

+754.03%

See Detailed Forecast

Company Profile

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 160.98% growth, versus a trailing 3-year CAGR of -42.11%.

2026
Current$8.2Baseline
Analyst Target - 1 year
Target$21.4+160.98%

All values in $

202220232024202520262027$22.10$36.83$51.55Target+160.98%
2026
Current$8.2Baseline
Analyst Target - 1 year
Target$21.4+160.98%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 754.03% growth, versus a trailing 3-year CAGR of -43.57%.

2025
Current$9.68Baseline
Forecast for Dec 2026
High$107.09+1005.89%
Average$82.70+754.03%
Low$52.1+438%

All values in $ Million

202120222023202420252026200.5753.9091.37135.159.68Low+438%Average+754.03%High+1005.89%
2025
Current$9.68Baseline
Forecast for Dec 2026
High$107.09+1005.89%
Average$82.70+754.03%
Low$52.1+438%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.98Baseline
Forecast for Dec 2026
High$0.64+116.08%
Average$0.64+116.08%
Low$0.64+116.08%

All values in $

2021202220232024202520261.09-2.51-2.8-2.3-3.98Low+116.08%Average+116.08%High+116.08%
2025
Current$-3.98Baseline
Forecast for Dec 2026
High$0.64+116.08%
Average$0.64+116.08%
Low$0.64+116.08%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2.4
-36.5
0
-21.5
51
32.7
1
-18.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.05132.010.972.122.824.422.410.0251.081.01
Net Income-72.2366.88-59-57.95-60.19-125.76-36.54-21.5832.72-18.58
Net Profit Margin-144478%50.66%-6082.57%-2729.91%-2128.53%-2845.40%-1513.08%-102804.76%64.05%-1839.90%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Prothena Corporation plc -1.470.8
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PRTA with any stock or ETF
Compare PRTA with any stock or ETF
Comparing from
PRTA
ABBV
AMGN
Loading...

Frequently asked questions

  1. Prothena Corporation plc (PRTA) share price today is $8.43 as of October 27, 2026 at 12:18 AM IST. The stock touched a day high of $8.48 and a day low of $8.22.

  2. Prothena Corporation plc stock trades on NASDAQ under the ticker symbol PRTA.

  3. Prothena Corporation plc's market capitalization is $420.96M as of October 27, 2026 at 12:18 AM IST.

  4. Prothena Corporation plc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Prothena Corporation plc's price-to-book (P/B) ratio is 1.47 as of October 26, 2026.

  6. Yes, You can buy Prothena Corporation plc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Prothena Corporation plc shares in three steps: 1. Search Prothena Corporation plc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Prothena Corporation plc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Prothena Corporation plc (PRTA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.1853 shares at the current price of $8.43.

Loading...